Paper8092845
In vitro activities of OPC-17116, a new quinolone; ofloxacin; and sparfloxacin against Chlamydia pneumoniae.
Roblin PM and 2 others. Antimicrob Agents Chemother, 1994. Cited by 33 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. In vitro activities of OPC-17116, a new quinolone; ofloxacin; and sparfloxacin against Chlamydia pneumoniae. Papers, record 8092845. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/8092845
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- In vitro activities of OPC-17116, a new quinolone; ofloxacin; and sparfloxacin against Chlamydia pneumoniae.
- PubMed
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Anti-Infective Agents | Major topic |
| Chlamydophila pneumoniae | Major topic |
| Fluoroquinolones | Major topic |
| Ofloxacin | Major topic |
| Piperazines | Major topic |
| Quinolones | Major topic |
| Microbial Sensitivity Tests |
Source PubMed
References10
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 2,973,283 | In vitro susceptibilities of mycoplasmas and ureaplasmas to new macrolides and aryl-fluoroquinolones. | Antimicrob Agents Chemother | 1988 | https://conductscience.org/library/papers/2973283 | PubMed |
| 2 | 2,181,028 | A new respiratory tract pathogen: Chlamydia pneumoniae strain TWAR. | J Infect Dis | 1990 | https://conductscience.org/library/papers/2181028 | PubMed |
| 3 | 2,252,040 | Ofloxacin treatment of Chlamydia pneumoniae (strain TWAR) lower respiratory tract infections. | Am J Med | 1990 | https://conductscience.org/library/papers/2252040 | PubMed |
| 4 | 2,010,629 | Infection with Chlamydia pneumoniae in Brooklyn. | J Infect Dis | 1991 | https://conductscience.org/library/papers/2010629 | PubMed |
| 5 | 1,571,425 | Persistent infection with Chlamydia pneumoniae following acute respiratory illness. | Clin Infect Dis | 1992 | https://conductscience.org/library/papers/1571425 | PubMed |
| 6 | 1,320,364 | In vitro and in vivo antibacterial activities of a new quinolone, OPC-17116. | Antimicrob Agents Chemother | 1992 | https://conductscience.org/library/papers/1320364 | PubMed |
| 7 | 1,320,366 | In vitro activities of five quinolones against Chlamydia pneumoniae. | Antimicrob Agents Chemother | 1992 | https://conductscience.org/library/papers/1320366 | PubMed |
| 8 | 8,494,377 | In vitro and in vivo antichlamydial activities of newly developed quinolone antimicrobial agents. | Antimicrob Agents Chemother | 1993 | https://conductscience.org/library/papers/8494377 | PubMed |
| 9 | 8,390,433 | The in-vitro activity of OPC-17116, a new 5-methyl substituted quinolone. | J Antimicrob Chemother | 1993 | https://conductscience.org/library/papers/8390433 | PubMed |
| 10 | 8,215,294 | Susceptibilities of Mycoplasma hominis, Mycoplasma pneumoniae, and Ureaplasma urealyticum to a new quinolone, OPC 17116. | Antimicrob Agents Chemother | 1993 | https://conductscience.org/library/papers/8215294 | PubMed |
Cited by9
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 33 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 11,600,398 | In vitro and in vivo activities of sitafloxacin against Chlamydia spp. | Antimicrob Agents Chemother | 2001 | https://conductscience.org/library/papers/11600398 | PubMed |
| 10,553,711 | Activity of quinolones against Chlamydia pneumoniae. | Drugs | 1999 | https://conductscience.org/library/papers/10553711 | PubMed |
| 9,785,106 | Daily oral grepafloxacin vs. twice daily oral doxycycline in the treatment of Chlamydia trachomatis endocervical infection. | Infect Dis Obstet Gynecol | 1998 | https://conductscience.org/library/papers/9785106 | PubMed |
| 9,624,507 | In vitro activity of a new ketolide antibiotic, HMR 3647, against Chlamydia pneumoniae. | Antimicrob Agents Chemother | 1998 | https://conductscience.org/library/papers/9624507 | PubMed |
| 9,559,818 | In vitro activity of a new 8-methoxyquinolone, BAY 12-8039, against Chlamydia pneumoniae. | Antimicrob Agents Chemother | 1998 | https://conductscience.org/library/papers/9559818 | PubMed |
| 9,303,410 | In vitro activity of trovafloxacin against Chlamydia pneumoniae. | Antimicrob Agents Chemother | 1997 | https://conductscience.org/library/papers/9303410 | PubMed |
| 8,894,585 | In vitro activity of trovafloxacin (CP-99,219), sparfloxacin, ciprofloxacin, and fleroxacin against respiratory pathogens. | Eur J Clin Microbiol Infect Dis | 1996 | https://conductscience.org/library/papers/8894585 | PubMed |
| 8,549,323 | Antichlamydial activities of newly developed fluoroquinolones and their potential future role in the treatment of chlamydial respiratory infections. | Drugs | 1995 | https://conductscience.org/library/papers/8549323 | PubMed |
| 7,810,992 | Antimicrobial susceptibility and therapy of infections caused by Chlamydia pneumoniae. | Antimicrob Agents Chemother | 1994 | https://conductscience.org/library/papers/7810992 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/8092845
GET https://conductscience.org/api/papers/v1/8092845/authors